Andrew Dunn

Fog­Phar­ma is re­nam­ing it­self as Para­bilis Med­i­cines, an­nounc­ing a new cor­po­rate iden­ti­ty Mon­day that re­flects the im­print left by CEO Math­ai Mam­men since join­ing in

David Bak­er has been push­ing the lim­its of de­sign­ing pro­teins for decades. The com­pu­ta­tion­al bi­ol­o­gist start­ed de­vel­op­ing soft­ware, called Roset­ta, to study and de­sign pro­teins

Benev­o­len­tAI’s CEO Jo­erg Moeller is step­ping down ef­fec­tive im­me­di­ate­ly, the Lon­don biotech said Thurs­day, in the lat­est lead­er­ship shake­up atop the com­pa­ny. Since go­ing pub­lic

Al­most a year ago, Sanofi made his­to­ry for the wrong rea­sons. Last Oc­to­ber, CEO Paul Hud­son an­nounced strate­gic changes in­clud­ing boost­ing R&D spend­ing and pulling

Ar­ti­fi­cial in­tel­li­gence has its No­bel Prize mo­ment. On Tues­day, the No­bel Prize in Physics went to a pair of long­time AI pi­o­neers in Ge­of­frey Hin­ton

Atom­wise’s found­ing CEO Abra­ham Heifets has left the com­pa­ny af­ter a dozen years, End­points News has learned, in the lat­est chal­lenge for one of the

Jim Collins, the famed MIT pro­fes­sor and a god­fa­ther of the syn­thet­ic bi­ol­o­gy field, de­scribes Fe­lix Wong as one of the most tal­ent­ed re­searchers to